Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Boon

Showing results (101-110 of 128) with videos related to

Pageof 13
Sort By:
Journal of Alzheimer'S Disease : JAD|July 25, 2018
Quantitative PET and Histology of Brain Biopsy Reveal Lack of Selective Pittsburgh Compound-B Binding to Intracerebral AmyloidomaColin Groot, Nelleke Tolboom, Milos D Ikonomovic, et al.
Translational Psychiatry|March 1, 2023
Translatability of preclinical to early clinical tolerable and pharmacologically active dose ranges for central nervous system active drugsGuilherme S Ferreira, Francis M Dijkstra, Désirée H Veening-Griffioen, et al.
Malaria Journal|September 13, 2023
The impact of anti-malarial markets on artemisinin resistance: perspectives from Burkina FasoRosemonde M Guissou, Chanaki Amaratunga, Freek de Haan, et al.
Wellcome Open Research|August 30, 2021
Ethical, Regulatory and Market related aspects of Deploying Triple Artemisinin-Based Combination Therapies for Malaria treatment in Africa: A study protocolPaulina Tindana, Freek de Haan, Olugbenga Ayodeji Mokuolu, et al.
Plos One|August 31, 2021
To what extent are the antimalarial markets in African countries ready for a transition to triple artemisinin-based combination therapies?Freek de Haan, Oladimeji Akeem Bolarinwa, Rosemonde Guissou, et al.
Neuropathology and Applied Neurobiology|February 13, 2022
The severity of behavioural symptoms in FTD is linked to the loss of GABRQ-expressing VENs and pyramidal neuronsPriya Gami-Patel, Marta Scarioni, Femke H Bouwman, et al.
Brain Communications|September 21, 2020
Can <i>post-mortem</i> MRI be used as a proxy for <i>in vivo</i>? A case studyBaayla D C Boon, Petra J W Pouwels, Laura E Jonkman, et al.
Alzheimer'S Research & Therapy|April 25, 2025
Clinical phenotypes of Alzheimer's disease: investigating atrophy patterns and their pathological correlatesNiels Reijner, I Frigerio, M M A Bouwman, et al.
Brain Communications|December 20, 2021
Amyloid-β, p-tau and reactive microglia are pathological correlates of MRI cortical atrophy in Alzheimer's diseaseIrene Frigerio, Baayla D C Boon, Chen-Pei Lin, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|April 25, 2025
2024 Alzheimer's Association criteria for Alzheimer's disease diagnosis are usually anchored to both plaques and tangles, not Aβ aloneClifford R Jack, David S Knopman, Heather J Wiste, et al.
Pageof 13

Showing results (101-110 of 128) with videos related to

Sort By:
Pageof 13
Journal of Alzheimer'S Disease : JAD|July 25, 2018
Quantitative PET and Histology of Brain Biopsy Reveal Lack of Selective Pittsburgh Compound-B Binding to Intracerebral AmyloidomaColin Groot, Nelleke Tolboom, Milos D Ikonomovic, et al.
Translational Psychiatry|March 1, 2023
Translatability of preclinical to early clinical tolerable and pharmacologically active dose ranges for central nervous system active drugsGuilherme S Ferreira, Francis M Dijkstra, Désirée H Veening-Griffioen, et al.
Malaria Journal|September 13, 2023
The impact of anti-malarial markets on artemisinin resistance: perspectives from Burkina FasoRosemonde M Guissou, Chanaki Amaratunga, Freek de Haan, et al.
Wellcome Open Research|August 30, 2021
Ethical, Regulatory and Market related aspects of Deploying Triple Artemisinin-Based Combination Therapies for Malaria treatment in Africa: A study protocolPaulina Tindana, Freek de Haan, Olugbenga Ayodeji Mokuolu, et al.
Plos One|August 31, 2021
To what extent are the antimalarial markets in African countries ready for a transition to triple artemisinin-based combination therapies?Freek de Haan, Oladimeji Akeem Bolarinwa, Rosemonde Guissou, et al.
Neuropathology and Applied Neurobiology|February 13, 2022
The severity of behavioural symptoms in FTD is linked to the loss of GABRQ-expressing VENs and pyramidal neuronsPriya Gami-Patel, Marta Scarioni, Femke H Bouwman, et al.
Brain Communications|September 21, 2020
Can <i>post-mortem</i> MRI be used as a proxy for <i>in vivo</i>? A case studyBaayla D C Boon, Petra J W Pouwels, Laura E Jonkman, et al.
Alzheimer'S Research & Therapy|April 25, 2025
Clinical phenotypes of Alzheimer's disease: investigating atrophy patterns and their pathological correlatesNiels Reijner, I Frigerio, M M A Bouwman, et al.
Brain Communications|December 20, 2021
Amyloid-β, p-tau and reactive microglia are pathological correlates of MRI cortical atrophy in Alzheimer's diseaseIrene Frigerio, Baayla D C Boon, Chen-Pei Lin, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|April 25, 2025
2024 Alzheimer's Association criteria for Alzheimer's disease diagnosis are usually anchored to both plaques and tangles, not Aβ aloneClifford R Jack, David S Knopman, Heather J Wiste, et al.
Pageof 13